Christopher Hoimes

7.9k total citations · 2 hit papers
129 papers, 3.0k citations indexed

About

Christopher Hoimes is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Christopher Hoimes has authored 129 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Oncology, 69 papers in Surgery and 35 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Christopher Hoimes's work include Cancer Immunotherapy and Biomarkers (67 papers), Bladder and Urothelial Cancer Treatments (65 papers) and Urinary and Genital Oncology Studies (36 papers). Christopher Hoimes is often cited by papers focused on Cancer Immunotherapy and Biomarkers (67 papers), Bladder and Urothelial Cancer Treatments (65 papers) and Urinary and Genital Oncology Studies (36 papers). Christopher Hoimes collaborates with scholars based in United States, France and United Kingdom. Christopher Hoimes's co-authors include Sandy Srinivas, Terence W. Friedlander, Nicholas J. Vogelzang, Peter H. O’Donnell, Daniel P. Petrylak, Jonathan E. Rosenberg, Efstathios Karathanasis, Jingsong Zhang, Joyce Antal and Noah M. Hahn and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Christopher Hoimes

119 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

2017 664 citations Peter H. O’Donnell, Terence W. Friedlander et al. profile →
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer

2022 163 citations Christopher Hoimes, Thomas W. Flaig et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher Hoimes United States	28	1.6k	1.3k	634	539	517	129	3.0k
Alan N. Gordon United States	26	1.5k 1.0×	1.1k 0.8×	324 0.5×	697 1.3×	755 1.5×	50	3.8k
Michael T. Spiotto United States	27	1.6k 1.0×	423 0.3×	926 1.5×	763 1.4×	1.2k 2.3×	99	3.8k
Rutger‐Jan Swijnenburg Netherlands	31	1.1k 0.7×	1.4k 1.0×	740 1.2×	1.1k 2.0×	134 0.3×	134	3.6k
Yanling Ma United States	28	762 0.5×	909 0.7×	766 1.2×	609 1.1×	98 0.2×	100	2.7k
Ronald L. Korn United States	21	1.4k 0.9×	421 0.3×	771 1.2×	664 1.2×	206 0.4×	84	3.0k
Jinming Yu China	19	1.2k 0.8×	285 0.2×	671 1.1×	579 1.1×	501 1.0×	66	2.3k
Si Yeol Song South Korea	27	774 0.5×	511 0.4×	1.1k 1.7×	346 0.6×	210 0.4×	157	2.6k
Johannes J. Bonenkamp Netherlands	28	1.2k 0.8×	2.2k 1.6×	4.0k 6.3×	499 0.9×	535 1.0×	65	5.7k
Kenichi Taguchi Japan	37	1.7k 1.0×	1.4k 1.1×	1.1k 1.8×	1.2k 2.2×	83 0.2×	208	4.5k
Brandon Luber United States	24	2.5k 1.6×	590 0.4×	1.8k 2.8×	961 1.8×	764 1.5×	40	4.5k

Countries citing papers authored by Christopher Hoimes

Since Specialization

Citations

This map shows the geographic impact of Christopher Hoimes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Hoimes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Hoimes more than expected).

Fields of papers citing papers by Christopher Hoimes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Hoimes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Hoimes. The network helps show where Christopher Hoimes may publish in the future.

Co-authorship network of co-authors of Christopher Hoimes

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Hoimes. A scholar is included among the top collaborators of Christopher Hoimes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Hoimes. Christopher Hoimes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Myers, Sarah A., et al.. (2025). Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting. JAAD Case Reports. 58. 85–92.

Jiang, C.-Y., Omar Alhalabi, Edwin C. Oh, et al.. (2025). 3077P Enfortumab vedotin with pembrolizumab (EVP) treatment outcomes in patients with histologic subtypes of advanced urothelial carcinoma: Analysis of the UNITE study. Annals of Oncology. 36. S1489–S1489.

Friedlander, Terence W., Peter H. O’Donnell, Daniel P. Petrylak, et al.. (2025). 3074P EV-103 Cohort K: Efficacy and safety of enfortumab vedotin (EV) with or without pembrolizumab (P) in cisplatin (cis)-ineligible pts with previously untreated locally advanced or metastatic urothelial cancer (la/mUC) with a median (m) follow-up (FU) of ≈3.5 y. Annals of Oncology. 36. S1487–S1488.

Hansen, Aaron R., Alison Yan Zhang, Valentina Boni, et al.. (2025). A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301).. Journal of Clinical Oncology. 43(5_suppl).

Tirumani, Sree Harsha, et al.. (2024). Tumor mutational burden as a marker for radiologic response to immune checkpoint inhibitors. Current Problems in Diagnostic Radiology. 54(4). 460–464. 1 indexed citations

Pal, Sumanta K., Melissa A. Reimers, Benjamin Garmezy, et al.. (2024). A phase 1/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9–engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS2676–TPS2676. 4 indexed citations

Alhalabi, Omar, Dimitra Rafailia Bakaloudi, Amanda Nizam, et al.. (2024). Impact of squamous histology on outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma: Analysis of the UNITE study.. Journal of Clinical Oncology. 42(4_suppl). 651–651. 1 indexed citations

Hoimes, Christopher, Suzanne McGettigan, & Lee Schwartzberg. (2024). Onco-Primary Care of Patients Receiving Immune Checkpoint Inhibitors. The American Journal of Medicine. 137(12). 1200–1209. 1 indexed citations

Jiang, Changying, Omar Alhalabi, Amanda Nizam, et al.. (2024). 8P Factors associated with primary progression in patients with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV): Analysis of the UNITE study. ESMO Open. 9. 102263–102263. 1 indexed citations

10.

Nizam, Amanda, Li Zhang, Dimitra Rafailia Bakaloudi, et al.. (2024). 1972P Pre-treatment (Tx) risk factors for enfortumab vedotin-induced peripheral neuropathy (EVIPN) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of UNITE. Annals of Oncology. 35. S1142–S1142.

11.

Kotamarti, Srinath, et al.. (2023). Intratumoural immunotherapy plus focal thermal ablation for localized prostate cancer. Nature Reviews Urology. 21(5). 290–302. 13 indexed citations

12.

Hoimes, Christopher, Thomas W. Flaig, Matthew I. Milowsky, et al.. (2023). A Plain Language Summary Exploring a New Treatment Combination for Untreated Locally Advanced or Metastatic Urothelial Cancer: Enfortumab Vedotin Plus Pembrolizumab. Future Oncology. 20(7). 351–360. 3 indexed citations

13.

Shah, Neal, Matthew T. Campbell, Shifeng Mao, et al.. (2023). 1889P Phase Ib/II study of batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in combination with cabozantinib (cabo) in patients with advanced clear cell renal cell carcinoma (ccRCC) who failed first-line (1L) therapy. Annals of Oncology. 34. S1016–S1017.

14.

Hoimes, Christopher, Thomas W. Flaig, Matthew I. Milowsky, et al.. (2022). Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. Journal of Clinical Oncology. 41(1). 22–31. 163 indexed citations breakdown →

15.

McDermott, Ray, Emmanuel S. Antonarakis, Christopher Hoimes, et al.. (2020). KEYNOTE-199 cohorts 4 and 5: Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC). European Urology Open Science. 19. e885–e886. 2 indexed citations

16.

Atukorale, Prabhani U., Shruti Raghunathan, Taylor J. Moon, et al.. (2019). Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity. Cancer Research. 79(20). 5394–5406. 72 indexed citations

17.

Danila, Daniel C., Bruce Montgomery, Russell Z. Szmulewitz, et al.. (2016). A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC). Annals of Oncology. 27. vi565–vi565. 11 indexed citations

18.

Peiris, Pubudu M., Elizabeth Doolittle, Randall Toy, et al.. (2015). Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle. Cancer Research. 75(7). 1356–1365. 59 indexed citations

19.

Deng, Yang, Jennifer K. Saucier-Sawyer, Christopher Hoimes, et al.. (2014). The effect of hyperbranched polyglycerol coatings on drug delivery using degradable polymer nanoparticles. Biomaterials. 35(24). 6595–6602. 122 indexed citations

20.

Strimpakos, Alexios S, Christopher Hoimes, & Muhammad Wasif Saif. (2009). Pancreatic cancer: translating lessons from mouse models.. PubMed. 10(2). 98–103. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact